Klinik Araştırma Deneyimleri

​​​

• Sbul, Turkish Myeloma Study Group Thalidomid Multipmyelom Study, 2008-2011

• PI, Subkutan Rutiksimab Study, 2014-2016

• SubI, Relapse or Refractory DLBCL Study, 2013-2017

• SubI, Multipmyelom daramatumab Study, 2014-2018

• SubI, B32810006, Folicular Lymphoma, 2015-2018

• SubI, RI-01-006, Folicular Lymphoma, 2019-2021

• PI, Navitoclax- Ruxolitinib Combination, 2022-Halen

• PI, Allovir( P105-202), 2022-2024

• Pl, Monitor (BV-ITP-BP), 2023-2023

• Pl, CSL964-2001, 2023-2025

• Pl, Abbvie M16-191, 2022-2025

​